Skip to main content
2026 Prospectus
National Glaucoma Awareness Month 2026 executive observance hero.

· Executive Brief

National Glaucoma Awareness Month 2026

A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Greg Wahlstrom in his office at The Healthcare Executive
Written byMBAHCMPresident and Chief Executive Officer, The Healthcare ExecutiveOctober 2026 30 min read

Leadership signal

National Glaucoma Awareness Month can serve as an executive operating checkpoint.

Awareness can generate questions and requests for help. Executive teams can prepare by clarifying the first point of contact, the qualified team that accepts the request, the handoff standard, and the method used to verify completion without assuming that one route fits every person.

Start by distinguishing what is known from what the organization still needs to learn. A campaign plan, communication volume, or meeting count does not establish that a route is usable. Leaders need direct listening, clear ownership, locally defined measures, and a method for keeping exceptions visible.

Executive opening

Glaucoma is a follow-through problem that unfolds over years

Glaucoma damages vision quietly, so the health system’s task is less about a single diagnosis and more about keeping people in care for years. Case finding, referral, specialist access, daily eye-drop use and repeat testing all have to hold together. When one step slips, vision loss can progress before anyone notices.

The follow-through gap appears early. In a cohort of 1,466 patients with newly diagnosed primary open-angle glaucoma across U.S. health systems, 1,030 (70%) had one or more follow-up evaluations within 12 to 18 months of diagnosis.[15] Patients in the lowest wealth quartile had 5- to 9-fold lower odds of reaching the recommended pressure reduction than patients in higher quartiles.[15]

Daily treatment is equally fragile. At one academic eye institute, average medication adherence measured by proportion of days covered was 56.1% across 4,480 medically treated eyes.[3] A 10% lower proportion of days covered was associated with a higher likelihood of laser treatment, minimally invasive surgery and traditional surgery.[3] Adherence is therefore a capacity and cost issue as well as a quality issue.

Support can change the picture. In a randomized trial at two Michigan health systems, a six-month coaching program delivered by a nonphysician counselor raised electronically monitored adherence to 77.6%, compared with 58.0% among controls.[4] Access to specialists, meanwhile, is uneven: median drive times to the nearest glaucoma specialist ranged from 0.66 hours in the Northeast to 1.85 hours in the West.[1]

The sections that follow summarize peer-reviewed evidence on case finding, follow-up, adherence support, remote monitoring, disparities and measurement. They sit beside the executive guidance on this page and give leaders a shared factual base for deciding which handoff to strengthen first. Where the evidence is thin, especially on referral completion among Black and Hispanic adults, this page says so rather than filling the gap.

Current evidence

What the research says about follow-up, adherence and procedures

Follow-up and treatment outcomes track wealth and place. Among the 1,030 newly diagnosed patients with follow-up, 783 (76%) achieved 15% or greater intraocular pressure reduction in one or more eyes.[15] The odds of loss to follow-up were 61% lower in the wealthiest quartile than in the least-wealthy group (odds ratio 0.39).[15] Rural residents were more likely than urban residents to be lost to follow-up (odds ratio 5.54).[15] The authors concluded that clinicians and payers need ways to ensure that patients can access pressure-lowering interventions and receive guideline-based follow-up care.[15]

Adherence connects to procedure volume. Of the 4,480 eyes in the pharmacy-based study, 1,724 (38.5%) received medical treatment exclusively, while 2,756 (61.5%) underwent at least one procedure.[3] Laser treatment occurred in 31.2% of eyes, minimally invasive glaucoma surgery in 11.3% and traditional surgery in 19.0%.[3] A 10% lower adherence estimate was associated with a hazard ratio of 1.15 for traditional surgery.[3] Because the study was retrospective, it shows association rather than proof that lower adherence drives procedures.[3] In eyes with severe baseline disease, lower adherence correlated with traditional surgery but not with laser or minimally invasive procedures.[3]

Continuity is vulnerable to system shocks. In Lombardy, Italy, among 111,373 established patients, the risk of discontinuing glaucoma therapy was significantly higher during the COVID-19 pandemic (adjusted hazard ratio 1.17).[11] The pandemic was also associated with a marked reduction in new treatment initiations.[11] The authors highlighted the vulnerability of daily drop-based regimens to health care system disruptions.[11] Persistence was defined as continuous prescription refills allowing a 90-day grace period, a definition health systems can replicate in their own pharmacy data.[11]

Patients describe practical barriers. In a mixed-methods study of 44 patients with self-reported adherence of 80% or lower, patient-level factors were the most cited theme for both barriers (52%) and facilitators (48%).[5] Difficulty with the medication schedule was a leading barrier (48%), and the location of eye drops in the home (25%) was a leading facilitator.[5] In that cohort, patient-level factors were more significant barriers than factors related to health care.[5]

Taken together, the evidence shows that effective treatment exists, but many patients do not stay in follow-up or keep up daily medication, and the gaps follow wealth and geography.[15][3] These are pathway problems that health systems can measure, assign and improve, rather than individual failings to be addressed one visit at a time.

Figure 1

Glaucoma care leaks at follow-up and adherence, and support can narrow the gap

Glaucoma care leaks at follow-up and adherence, and support can narrow the gapPercent of patients or doses, as reported in each study (follow-up completion, adherence or retention in home monitoring). Values are copied from the cited studies [2], [3], [4], [15]; none is estimated.0%25%50%75%100%Newly diagnosed patients with follow-upwithin 12 to 18 monthsNewly diagnosed patients with follow-up within 12 to 18 months: 70% (source [15])70%[15]Average adherence by proportion of dayscoveredAverage adherence by proportion of days covered: 56.1% (source [3])56.1%[3]Doses taken on time with standardwritten educationDoses taken on time with standard written education: 58% (source [4])58%[4]Doses taken on time with nonphysiciancoachingDoses taken on time with nonphysician coaching: 77.6% (source [4])77.6%[4]Home perimetry participants still activeat 24 monthsHome perimetry participants still active at 24 months: 86.7% (source [2])86.7%[2]Source [15]Source [3]Source [4]Source [2]Shade and hatching group bars by study; the studies differ in population and setting, so bars compare only within a shade

Percent of patients or doses, as reported in each study (follow-up completion, adherence or retention in home monitoring). Values are copied from the cited studies [2], [3], [4], [15]; none is estimated.

Data note. Except for the two trial arms, these values come from different studies, settings and definitions, so this is an indirect comparison; the bars show where the pathway leaks and how much support can recover, not a ranking.

Limitation. Adherence is measured by pharmacy claims in one study and by electronic monitoring in another; follow-up is measured in a retrospective cohort; home monitoring retention is from a selected research cohort.

Figure data (5 rows)
Figure 1 data: Glaucoma care leaks at follow-up and adherence, and support can narrow the gap
MeasureValuePopulation, setting and year as reportedSource
Newly diagnosed patients with follow-up within 12 to 18 months70%1,030 of 1,466 patients with newly diagnosed primary open-angle glaucoma, U.S. health systems, 2010 to 2022[15]
Average adherence by proportion of days covered56.1%4,480 medically treated eyes at one U.S. academic eye institute, 2015 to 2025[3]
Doses taken on time with standard written education58%Control group of a randomized trial at two Michigan health systems, six months[4]
Doses taken on time with nonphysician coaching77.6%Intervention group of the same randomized trial, six months[4]
Home perimetry participants still active at 24 months86.7%Eligible participants in a prospective cohort of 53 patients with open-angle glaucoma[2]
An optometric technician guides an older Black man to rest his chin on an eye pressure device.
Illustrative image. Only 70% of newly diagnosed patients in one U.S. cohort had follow-up within 12 to 18 months.[15]

Continuum of care

Where glaucoma care breaks between case finding, referral and long-term monitoring

Glaucoma care is a long continuum. It begins with case finding in the community or primary care, moves through referral and diagnosis, and continues through years of treatment and monitoring. Each handoff carries its own risk that a patient will drop out without anyone noticing. At each handoff, the useful executive question is who knows when a patient has not arrived.

Case finding is becoming more portable. At a Nigerian teaching hospital, 312 participants (524 eyes) were tested with portable devices and with standard diagnostic tools.[8] A handheld fundus camera achieved the highest diagnostic accuracy (area under the curve 0.91; sensitivity 82.4%, specificity 99.8%).[8] Portable devices were faster, had higher completion rates and were strongly preferred by participants, although the authors recommended further community-based validation.[8] Strong correlations were also reported between portable and standard pressure readings (r = 0.96).[8]

Primary care can extend the front door. In Shenzhen, China, a training model for general practitioners combined structured curricula, clinical mentorship and AI-assisted screening tools.[9] AI-enabled screening during community training reached approximately 33,000 residents, with a positive detection rate of 11.2%.[9] Detection at that scale creates referral volume, so a screening program needs a receiving pathway sized to what it finds.

Monitoring between visits can keep patients visible. A clinician-led telemonitoring platform followed 30 glaucoma patients from May 2025 to April 2026 with symptom workflows, medication reminders and two-way messaging.[10] Structured monitoring identified suspected treatment-related adverse reactions in two patients, prompting earlier clinical reassessment and treatment adjustment.[10] Its central design feature was a configurable protocol engine that turns static symptom forms into patient-specific workflows.[10] The authors called for larger multicenter studies of effectiveness, safety, workflow burden and cost-effectiveness.[10]

Home testing can sustain engagement over time. In a prospective study of weekly home virtual reality perimetry, 53 patients (106 eyes) were followed for a mean of 16.6 months and completed 4,817 home tests.[2] At 24 months, 86.7% of eligible participants remained active, with a mean frequency of more than two tests per month.[2] Higher-frequency home testing improved the precision of progression estimates, which supports home perimetry as an adjunct to office testing.[2] The study enrolled a selected research cohort, so routine programs should expect to test retention locally before scaling.

Figure 3

Why the pathway breaks

Cause-and-effect diagram: Patients with or at risk for glaucoma are not found, referred, followed up or supported to keep up treatmentUnranked qualitative cause-and-effect diagram for the outcome in the box: Patients with or at risk for glaucoma are not found, referred, followed up or supported to keep up treatment Causes are assembled from the cited literature [1], [3], [4], [5], [6], [8], [9], [10], [11], [13], [14], [15]; categories are not weighted and their order carries no meaning.Patients with or at risk forglaucoma are not found,referred, followed up orsupported to keep up treatmentPeopleProcessTechnologyEnvironmentPolicyMeasurement

People

  • No counselor or pharmacist role for adherence support
  • Primary care clinicians without eye care training
  • Cognitive and comorbidity barriers not identified

Process

  • Screening without a receiving referral pathway
  • No outreach after missed follow-up
  • Medication schedule hard to fit into daily routines

Technology

  • Portable case-finding devices not deployed
  • Remote monitoring signals with no assigned reviewer
  • Refill gaps not visible to the care team

Environment

  • Long drive times to specialists in rural and western counties
  • Neighborhood disadvantage
  • System disruptions such as a pandemic

Policy

  • Cost barriers for lower-wealth patients
  • Treatment patterns that diverge by race
  • Limited coverage for coaching and remote testing

Measurement

  • Loss to follow-up not tracked after diagnosis
  • Adherence not measured with a standard tool
  • Results not stratified by wealth, rurality, race or ethnicity

Unranked qualitative cause-and-effect diagram for the outcome in the box: Patients with or at risk for glaucoma are not found, referred, followed up or supported to keep up treatment Causes are assembled from the cited literature [1], [3], [4], [5], [6], [8], [9], [10], [11], [13], [14], [15]; categories are not weighted and their order carries no meaning.

Data note. Qualitative; no frequencies are implied.

Limitation. Causes drawn from published studies may not all apply locally; validate them with frontline teams.

Figure data (6 rows)
Figure 3 data: Why the pathway breaks
CategoryCauses drawn from the cited literature
PeopleNo counselor or pharmacist role for adherence support; Primary care clinicians without eye care training; Cognitive and comorbidity barriers not identified
ProcessScreening without a receiving referral pathway; No outreach after missed follow-up; Medication schedule hard to fit into daily routines
TechnologyPortable case-finding devices not deployed; Remote monitoring signals with no assigned reviewer; Refill gaps not visible to the care team
EnvironmentLong drive times to specialists in rural and western counties; Neighborhood disadvantage; System disruptions such as a pandemic
PolicyCost barriers for lower-wealth patients; Treatment patterns that diverge by race; Limited coverage for coaching and remote testing
MeasurementLoss to follow-up not tracked after diagnosis; Adherence not measured with a standard tool; Results not stratified by wealth, rurality, race or ethnicity

Access

Access to specialists, testing and adherence support

Specialist access varies sharply by geography. Across the contiguous states, mean drive times to the nearest glaucoma specialist ranged from 0.04 hours in the District of Columbia to 3.77 hours in North Dakota.[1] Metro core counties had the lowest median drive time (0.23 hours), while small-town cores and rural counties had medians of 1.16 and 1.02 hours.[1] The authors called for targeted outreach, teleophthalmology expansion and workforce planning.[1]

State averages hide local gaps. The proportion of counties with drive times below the state mean ranged from 2% in Delaware and Rhode Island to roughly 80% in Georgia.[1] A health system’s own service-area analysis is therefore more useful than a state figure for deciding where to place outreach or remote testing. Rural residence was also associated with higher odds of loss to follow-up in the newly diagnosed cohort, which links distance to continuity.[15]

Adherence support is itself an access question. The coaching program in the Michigan trial included 3 in-person sessions, 4 between-visit phone calls, personalized multimedia education and automated medication reminders over six months.[4] The control group received usual care and 3 mailings of standard written education.[4] The difference in adherence between groups was 19.7%, and the program also reduced glaucoma-related distress.[4]

Pharmacists offer another route to support. In a quasi-experimental pilot at a Baghdad teaching hospital, 94 adults with primary open-angle glaucoma received a 30–40 minute individualized session on drop technique and adherence, designed around the Health Belief Model.[12] The authors reported significant improvements in adherence, drop administration accuracy and pressure-target attainment, and called for larger studies with longer follow-up.[12] Because the pilot had no control group, its main value for executives is as a model of a pharmacist role rather than as a measure of effect.[12]

Remote tools can reduce the travel burden of monitoring. Home perimetry tests were shorter than office tests, at 4.93 versus 5.80 minutes on average.[2] For patients facing long drives, a well-supported home or community option may determine whether monitoring happens at all. Each of these routes widens access only if a clinician is assigned to act on what it finds. Teleophthalmology expansion was one of the specific remedies the drive-time authors proposed.[1]

Executive guidance · System route

Build one visible operating route for National Glaucoma Awareness Month.

Use this route as a discussion framework. Replace each stage with the organization’s approved process, qualified roles, current service capacity, and applicable requirements. Do not infer a clinical protocol from the observance title.

The route at a glance

  1. Listen
  2. Clarify entry
  3. Design for visual access
  4. Protect transitions
  5. Verify and learn

Reliability rule: Every stage needs a named owner, an observable status, an approved escalation path, and a defined signal that shows whether responsibility moved or remained unresolved.

  1. Listen

    Gather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.

  2. Clarify entry

    Publish a plain-language first step and identify who receives requests through each approved channel.

  3. Design for visual access

    Review whether information, digital channels, physical wayfinding, and transition instructions are usable with locally appropriate access support.

  4. Protect transitions

    Use acknowledgment and status visibility when responsibility moves between services, locations, or organizations.

  5. Verify and learn

    Review unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Figure 2

The system route as one flow

The system route as one flowThe five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.ListenClarify entryDesign forvisual accessProtecttransitionsVerify and learnLearning returns to the start of the route

The five stages of the system route described in this brief, drawn as one flow with a learning loop back to the start. The stages are the page’s original executive guidance, not a clinical protocol.

Data note. Shows sequence and handoffs only; it carries no counts or rates.

Limitation. Local processes may add, merge or reorder stages under organizational policy.

Figure data (5 rows)
Figure 2 data: The system route as one flow
StageWhat the stage requires
ListenGather questions and friction points from people using the route, frontline teams, and community-facing staff. Separate observed barriers from assumptions.
Clarify entryPublish a plain-language first step and identify who receives requests through each approved channel.
Design for visual accessReview whether information, digital channels, physical wayfinding, and transition instructions are usable with locally appropriate access support.
Protect transitionsUse acknowledgment and status visibility when responsibility moves between services, locations, or organizations.
Verify and learnReview unresolved work, repeat contacts, and avoidable handoffs. Use the findings to improve the route rather than blame individuals.

Equity and trust

Disparities by wealth, geography, race and ethnicity

Equity gaps in glaucoma care follow wealth and place as clearly as race. The newly diagnosed cohort was diverse: 469 patients (32%) were Black, 95 (7%) were Latinx, 39 (3%) were Asian American and 831 (57%) were White.[15] Its strongest reported associations, however, were with wealth and rural residence.[15] The authors urged clinicians to understand patients’ financial circumstances when making management decisions.[15]

Neighborhood conditions shape adherence. In the barrier study, 45.5% of 44 participants were Black and 34% lived in high-disadvantage neighborhoods.[5] Patient-level barriers and facilitators differed by sex and by Area Deprivation Index.[5] Support that works in one neighborhood may therefore need adjustment in another, and programs should be evaluated by group rather than in aggregate.[5]

Treatment patterns can diverge by race. In a matched cohort of 3,410 patients with severe primary open-angle glaucoma, Asian American patients were less likely to receive topical medications (odds ratio 0.950) or laser procedures (odds ratio 0.769).[6] In mild-to-moderate disease, they were slightly more likely to receive topical medications (odds ratio 1.041).[6] The authors pointed to possible systemic or provider-level barriers to equitable care.[6] No significant differences were observed in surgical or minimally invasive surgery use.[6] The records spanned January 2004 to June 2025, so practice patterns may have shifted over that period.[6]

Awareness gaps are an equity issue in their own right. In a population-based survey of 4,993 respondents in Nepal, 78.2% had heard of at least one eye disease, but only 18.9% were aware of glaucoma.[7] Awareness differed by ethnicity, religion, education and occupation.[7] Among those aware, 67.6% did not know its cause and 48.4% were unaware of treatment options.[7] The authors urged targeted education for high-risk groups such as Dalits, housewives and daily wage laborers.[7]

The studies reviewed here offer limited direct data on referral completion among Black and Hispanic adults, which is itself a finding for governance. Executives can stratify their own screening, referral, follow-up and adherence measures by race, ethnicity, language, insurance, neighborhood and rurality.[15][5] Trust grows when the organization can show that the people at highest risk are the people who stay in care. That requires collecting race, ethnicity and language data reliably at intake, so that stratified reports reflect the whole population rather than the patients easiest to count.

An ophthalmologist examines the older man at a slit lamp in a dim exam room.
Illustrative image. Rural counties face longer drive times to glaucoma specialists than metro core counties.[1]

Human infrastructure

The people who keep glaucoma patients in care

Glaucoma pathways depend on more than glaucoma specialists. Primary care clinicians, optometrists, ophthalmic technicians, pharmacists, counselors and care coordinators each hold part of the route. When one role is missing, the gap usually appears as a missed visit or an unrefilled prescription rather than a visible failure.

Nonphysician counselors can carry adherence support. The Michigan trial enrolled 236 adults, randomized 235, and recorded a mean self-reported adherence of 63.9% at entry.[4] Coaching used motivational interviewing and was delivered by a nonphysician counselor rather than a physician.[4] Recruitment ran from April 2021 to December 2023 at an academic center and an integrated health system, so the model was tested in more than one operating environment.[4] The authors described the program as an evidence-based method to improve the adherence needed for better glaucoma outcomes.[4] Counseling roles need protected time and a defined place in the care team to deliver that result.

Training primary care clinicians takes sustained effort. In Shenzhen, two training cycles between 2019 and 2024 enrolled 117 general practitioners.[9] Graduation rates were 75% in 2023 (30 of 38) and 58.2% in 2024 (46 of 79), while participant satisfaction improved from 75.0% to 93.9%.[9] Completion fell as the cohort grew, so scale-up deserves its own monitoring.[9] AI-enabled screening tools were built into the training itself, so clinicians learned screening and referral together.[9]

Technology shifts work rather than removing it. In the telemonitoring pilot, 22 respondents (18 patients and 4 ophthalmologists) gave a mean System Usability Scale score of 79.43, an acceptable usability range.[10] The AI-assisted module remained exploratory and was not evaluated as an autonomous clinical component.[10] Remote signals still need a named clinician or technician who reviews them and acts.

Some patients need hands-on help. In a study of 187 glaucoma patients who underwent comprehensive geriatric assessment, lower cognitive scores were associated with knowledge-related adherence problems.[14] The assessment combined the Mini-Cog, the G8 and the Age-Adjusted Charlson Comorbidity Index.[14] Greater comorbidity burden was associated with technical difficulty instilling eye drops.[14] Staff who identify these barriers can match patients to the right support, from education to direct technique coaching.[14] A short questionnaire with separate knowledge and technique domains may help teams sort patients quickly, since its two-factor structure accounted for 71.2% of the total variance.[14]

Executive guidance · Operating dashboard

Use a small dashboard to expose friction and ownership.

Do not publish a number until the organization defines its numerator, denominator where relevant, owner, source system, exclusions, review cadence, and limits. The candidates below are management prompts, not benchmarks or reported results.

Four operating signals

Entry-point clarityOwnership reliabilityVisual usabilityImprovement closure

Each signal pairs an executive question with one candidate local measure, set out below.

Executive guidance · Signal

Entry-point clarity

Can people and staff identify the approved first step without searching across conflicting instructions?

Candidate local measure
Locally defined contact, routing, and repeat-contact signals by channel and service.

Executive guidance · Signal

Ownership reliability

Does a specific team accept each request and make its status visible?

Candidate local measure
Requests without an owner, aged work, transfers, and escalations using locally approved definitions.

Executive guidance · Signal

Visual usability

Do communication and navigation channels work for people with differing visual-access needs?

Candidate local measure
Locally defined format requests, wayfinding barriers, inaccessible content, repeat contacts, and corrective-action status.

Executive guidance · Signal

Improvement closure

Does the organization correct recurring friction and report what changed?

Candidate local measure
Selected barriers, assigned actions, completion status, and post-change review.

Figure 4

The operating system behind the dashboard

The operating system behind the dashboardThe four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.Accountableoperating route(executive sponsor)Entry-point clarityOwner: Executive sponsor andoperational leadOwnership reliabilityOwner: Operational owner andparticipating teamsVisual usabilityOwner: Sending and receiving ownersImprovement closureOwner: Improvement owner andexecutive sponsor

The four operating signals from this brief’s dashboard, each tied to the candidate owner named in the executive scorecard, around one accountable route. Drawn from the page’s original executive guidance.

Data note. Structural diagram; no measured values.

Limitation. Owners are candidates to be confirmed locally.

Figure data (4 rows)
Figure 4 data: The operating system behind the dashboard
Operating signalCandidate owner
Entry-point clarityExecutive sponsor and operational lead
Ownership reliabilityOperational owner and participating teams
Visual usabilitySending and receiving owners
Improvement closureImprovement owner and executive sponsor

Executive guidance · Handoff workflow

Close the loop across teams, settings, and partners.

A handoff is reliable only when the sending party knows who is expected to receive the work, the receiving party acknowledges responsibility, and any unresolved exception remains visible. Local policy and qualified judgment control the actual process.

How responsibility moves

Lane AFrom message to accepted ownership4 steps
Lane BFrom accepted ownership to verified follow-through4 steps

Lane A

From message to accepted ownership

  1. Confirm the approved message and intended audience.
  2. Publish the actual entry point and receiving role.
  3. Acknowledge receipt using the locally approved method.
  4. Escalate when ownership or response remains unclear.

Lane B

From accepted ownership to verified follow-through

  1. Record the next accountable owner and visible status.
  2. Record any locally approved communication or access support needed for the next step without making assumptions.
  3. Keep unresolved work visible across boundaries.
  4. Confirm closure or document the continuing exception.

Executive guidance · Executive scorecard

Give leaders one view of route reliability and improvement.

The scorecard keeps review focused on decisions. Leaders should set definitions locally, examine variation without overclaiming cause, and pair quantitative signals with the experience of people who use and operate the route.

Who reviews what

  • Executive sponsor and operational lead
  • Operational owner and participating teams
  • Sending and receiving owners
  • Improvement owner and executive sponsor

Candidate owners named in the scorecard, confirmed locally.

Candidate questions and ownership assignments. These are not external benchmarks.
Operating signalExecutive questionCandidate ownerSuggested review point
Entry-point clarityCan people and staff identify the approved first step without searching across conflicting instructions?Executive sponsor and operational leadAt campaign launch and close
Ownership reliabilityDoes a specific team accept each request and make its status visible?Operational owner and participating teamsAt a locally defined cadence
Visual usabilityDo communication and navigation channels work for people with differing visual-access needs?Sending and receiving ownersAt a locally defined cadence
Improvement closureDoes the organization correct recurring friction and report what changed?Improvement owner and executive sponsorUntil action is verified

Figure 5

Control points for a reliable glaucoma care pathway

Figure 5: Control points for a reliable glaucoma care pathway
Control pointRisk if missingOwnerEvidence of control
Referral pathway for positive community or primary care screensDetected patients are never seen by eye careAmbulatory operations lead with ophthalmology service chiefShare of positive screens with a completed eye care visit
Follow-up tracking after new diagnosisPatients are lost to follow-up, especially in rural and lower-wealth groupsOphthalmology practice managerShare of new patients with follow-up within 12 to 18 months, stratified by group
Pharmacy-based adherence monitoringRefill gaps go unnoticed until disease progressesPharmacy director with glaucoma clinic leadProportion of days covered reported by clinic and patient group
Adherence coaching by counselors or pharmacistsPatients with low adherence receive only written materialsChief nursing officer or pharmacy directorPatients referred to and completing coaching
Assigned review of remote monitoring signalsHome tests and alerts are collected but not acted onGlaucoma service medical directorTime from alert to clinical review
Geographic access planRural and western patients face long drivesStrategy and network development leadDrive-time analysis of the service area and outreach sites added
Stratified quality reporting to the boardDisparities by wealth, rurality and race stay hiddenChief quality officer and board quality committeeFollow-up, adherence and pressure-target measures reported by group

Control points derived from the cited evidence [1], [2], [3], [4], [10], [12], [15] and this brief’s executive guidance.

Data note. Each row is a control to verify, not a measured result.

Limitation. Owners and evidence of control must follow local policy and applicable requirements.

Public communication

Communicating about glaucoma so that people act and stay in care

Awareness is a starting point, not a result. The Nepal survey authors recommended targeted community-based education for high-risk groups, integration of glaucoma awareness and screening within primary health care, local media and engagement of community health workers.[7] Those recommendations describe a communication system rather than a single campaign.[7]

Communication between visits matters as much as outreach. The telemonitoring platform recorded 737 engaged sessions, 1,329 events, 30 bidirectional messages and 186 questionnaire responses across its environment.[10] Two-way channels can surface problems between appointments, provided the clinical team can respond.[10] Its usability score fell in the good adjective rating range, which suggests patients and ophthalmologists found the channel workable.[10] Patients are more likely to trust a channel that answers them than one that only sends reminders.

Practical messages may help more than general ones. In the barrier study, the medication schedule was a leading barrier and the place where drops were kept at home was a leading facilitator.[5] In the Michigan trial, personalized multimedia education within coaching outperformed standard written education mailed to patients.[4] Messages tied to daily routines, delivered by someone the patient knows, fit what these studies found.[4][5]

Measurement is part of communication with boards. A Delphi panel of 16 experts reached consensus levels of 81.0% and 89.0% across two rounds.[13] It identified the Glaucoma Treatment Compliance Assessment Tool short form as the most appropriate tool for measuring nonadherence, with a content validity index of 0.91 and an intraclass correlation of 0.94.[13] Agreement on nonadherence characteristics was high, with content validity and intraclass correlation values above 0.75.[13] Pharmacy-based proportion of days covered offers a complementary, scalable system measure.[3]

The newly diagnosed cohort used the National Quality Forum’s recommended pressure reduction as an outcome, which gives leaders an established benchmark to report.[15] Executives can review follow-up completion, adherence and pressure-target attainment together, stratified by wealth and geography.[15][3] Public messages earn trust when the services they promote can absorb the response they generate. Reporting by group also helps leaders explain to communities what the organization is doing about the gaps they experience.

The older man places his eye drops at the kitchen table while his wife pours coffee.
Illustrative image. Patients cited keeping eye drops in a set place at home as a leading facilitator of adherence.[5]

Executive guidance · 90-day plan

Turn the observance into one sustained operating change.

The time boxes below are a management framework, not a clinical timeline. Adjust them to risk, scope, governance, resources, stakeholder participation, and applicable review requirements.

Ninety days, three moves

  1. Days 1–30See the current route
  2. Days 31–60Build the reliable path
  3. Days 61–90Make the change visible

Days 1–30 · Listen and map

See the current route

  • Name an executive sponsor and an operational owner.
  • Listen to people using the route and representative frontline teams.
  • Map how National Glaucoma Awareness Month communications connect to real entry points, owners, transitions, and escalation.
  • Select one recurring barrier that the organization can responsibly address.

Days 31–60 · Design and test

Build the reliable path

  • Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
  • Validate the design with every sending and receiving team involved.
  • Audit one high-use communication or navigation route for visual usability and correct a verified barrier.
  • Test the route in more than one representative setting or operating period where practical.

Days 61–90 · Implement and verify

Make the change visible

  • Launch the redesigned route with a small set of locally defined measures.
  • Review unresolved work and recurring friction using a learning approach.
  • Correct implementation barriers and record who owns each remaining dependency.
  • Report what changed, what evidence was reviewed, and what still requires live oversight.

Figure 6

The 90-day plan on one timeline

The 90-day plan on one timelineThe 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.Day 0Day 30Day 60Day 90Name an executive sponsor and an operational owner.Days 1–30: Name an executive sponsor and an operational owner.Listen to people using the route and representative frontlineteams.Days 1–30: Listen to people using the route and representative frontline teams.Map how National Glaucoma Awareness Month communicationsconnect to real entry points, owners, transitions, andescalation.Days 1–30: Map how National Glaucoma Awareness Month communications connect to real entry points, owners, transitions, and escalation.Select one recurring barrier that the organization canresponsibly address.Days 1–30: Select one recurring barrier that the organization can responsibly address.Define the trigger, receiving owner, required information,acknowledgment, escalation, and closure signal.Days 31–60: Define the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.Validate the design with every sending and receiving teaminvolved.Days 31–60: Validate the design with every sending and receiving team involved.Audit one high-use communication or navigation route forvisual usability and correct a verified barrier.Days 31–60: Audit one high-use communication or navigation route for visual usability and correct a verified barrier.Test the route in more than one representative setting oroperating period where practical.Days 31–60: Test the route in more than one representative setting or operating period where practical.Launch the redesigned route with a small set of locallydefined measures.Days 61–90: Launch the redesigned route with a small set of locally defined measures.Review unresolved work and recurring friction using a learningapproach.Days 61–90: Review unresolved work and recurring friction using a learning approach.Correct implementation barriers and record who owns eachremaining dependency.Days 61–90: Correct implementation barriers and record who owns each remaining dependency.Report what changed, what evidence was reviewed, and whatstill requires live oversight.Days 61–90: Report what changed, what evidence was reviewed, and what still requires live oversight.Listen and mapDesign and testImplement and verify

The 90-day plan from this brief drawn as a timeline: each action sits in the 30-day window the plan assigns it. The full wording of each action is in the figure data and in the plan above.

Data note. Time boxes are a management framework, not a clinical timeline.

Limitation. Durations are uniform 30-day windows; real tasks may span windows.

Figure data (12 rows)
Figure 6 data: The 90-day plan on one timeline
WindowAction
Days 1–30 · Listen and mapName an executive sponsor and an operational owner.
Days 1–30 · Listen and mapListen to people using the route and representative frontline teams.
Days 1–30 · Listen and mapMap how National Glaucoma Awareness Month communications connect to real entry points, owners, transitions, and escalation.
Days 1–30 · Listen and mapSelect one recurring barrier that the organization can responsibly address.
Days 31–60 · Design and testDefine the trigger, receiving owner, required information, acknowledgment, escalation, and closure signal.
Days 31–60 · Design and testValidate the design with every sending and receiving team involved.
Days 31–60 · Design and testAudit one high-use communication or navigation route for visual usability and correct a verified barrier.
Days 31–60 · Design and testTest the route in more than one representative setting or operating period where practical.
Days 61–90 · Implement and verifyLaunch the redesigned route with a small set of locally defined measures.
Days 61–90 · Implement and verifyReview unresolved work and recurring friction using a learning approach.
Days 61–90 · Implement and verifyCorrect implementation barriers and record who owns each remaining dependency.
Days 61–90 · Implement and verifyReport what changed, what evidence was reviewed, and what still requires live oversight.

Executive guidance · Leadership close

Make National Glaucoma Awareness Month a starting point, not an endpoint.

Recognition matters. It becomes durable when leaders also listen, clarify the route, support the people operating it, close an identified gap, and report the result without claiming more than the evidence supports.

Leadership commitment

Make ownership visible, test the route, and report what improved.

Executive action kit · Month observance

Turn National Glaucoma Awareness Month into accountable action.

A practical executive framework for access, ownership, handoffs, measurement, and improvement.

Take it with you

Filed under

Chronic Disease and Specialty CarePublic Health and PreventionMonth

Leadership focus

Use this observance to examine navigation, longitudinal ownership, and specialty-care coordination. Select one verified barrier, assign an accountable owner, and carry the improvement beyond the campaign window.

Workforce lens

Ask whether staffing, role clarity, training, tools, workload, and escalation support the people operating the accessible information, evaluation navigation, accommodation, and follow-through pathway.

Patient and community lens

Make the approved first step clear. Test whether a person can move from information to an acknowledged next action without navigating conflicting instructions.

Equity and access lens

Review visual accessibility, language, transportation, digital design, disability accommodation, and access to appropriate services.

Five-minute briefing

Inspect the operating sequence

Listen with people using the pathway, caregivers, eye-care services, primary care, rehabilitation, and access teams. Find one inaccessible information, unclear entry, or a referral that is not completed, then test the locally approved route from entry through acknowledged follow-through.

  1. Listen
  2. Clarify entry
  3. Design for visual access
  4. Protect transitions
  5. Verify and learn
Leadership actions for this week
  • Name an executive sponsor and frontline operating owner.
  • Ask people using and operating the pathway where ownership becomes unclear.
  • Test one representative route from first question to acknowledged next step.
  • Select one barrier that can be corrected without overstating the evidence.
  • Set a review date and define how completion will be verified.
Candidate measures

Define every numerator, denominator where relevant, owner, data source, exclusions, cadence, and limitation locally. These are management prompts, not external benchmarks.

  • Locally defined contact, routing, and repeat-contact signals by channel and service.
  • Requests without an owner, aged work, transfers, and escalations using locally approved definitions.
  • Locally defined format requests, wayfinding barriers, inaccessible content, repeat contacts, and corrective-action status.
Department readiness checklist
  • The public and staff entry points match the actual approved process.
  • A specific role accepts each request, referral, or escalation.
  • Handoffs include acknowledgment and a visible unresolved state.
  • Language, disability, digital, transportation, and trust barriers receive explicit review.
  • Communications do not introduce unsupported themes, statistics, or clinical advice.
  • A named leader will review what changed after the observance.
Intended audiences
  • Executive and Operational Leaders
  • Patient Experience and Access Leaders
Staff communication template

During National Glaucoma Awareness Month, our organization will connect awareness with a practical review of the accessible information, evaluation navigation, accommodation, and follow-through pathway. Use approved information, identify the correct entry point, confirm ownership when work moves, protect privacy, and escalate unresolved barriers through local channels.

Community communication template

National Glaucoma Awareness Month is an opportunity to share trustworthy information and make the next step easier to find. Use our approved channels for information and support. If a request changes hands, our goal is to keep ownership and follow-through visible.

Measurement worksheet
Signal
What observable condition will show whether the route works?
Definition
What is included, excluded, and counted?
Owner
Who reviews the signal and acts on exceptions?
Cadence
When will leaders review it?
Equity check
Which differences require protected, locally appropriate review?
Closure
What evidence will confirm the improvement was completed?
Editorial review
Completed
Source records
2 listed under Authoritative resources
Review standard
Sourced facts remain separated from original executive guidance
Clinical boundary
No new statistical or clinical claim was added by this action kit

Sources and content boundary

Authoritative resources

Use note: All operating models, measures, scorecard questions, and action steps are original executive guidance. This article supports leadership planning and education. It does not replace clinical judgment, emergency procedures, legal advice, professional standards, organizational policy, or applicable federal, state, and local requirements.

Peer-reviewed references

References

Fifteen peer-reviewed sources, newest first. Each was individually verified through authenticated academic research databases. Bracketed numbers in the text link here; the original executive guidance on this page carries no citations because it is guidance, not a sourced claim. Sources last checked in those databases on .

  1. 1. Geographic Distribution and Drive Times to Glaucoma Specialists in the United States: A National Geospatial Access Analysis and Drive-Time Study. Ophthalmology Glaucoma. 2026. https://doi.org/10.1016/j.ogla.2026.04.005
  2. 2. Weekly Home Monitoring of Glaucoma with Virtual Reality Perimetry. Ophthalmology Glaucoma. 2026. https://doi.org/10.1016/j.ogla.2026.08.007
  3. 3. The Association between a Pharmacy-Based Estimate of Medication Adherence and Surgical and Laser Treatments in Patients with Glaucoma. Ophthalmology Glaucoma. 2026;9(5):494-504. https://doi.org/10.1016/j.ogla.2026.02.005
  4. 4. Effect of the Support, Educate, Empower Personalized Glaucoma Coaching Program on Medication Adherence. JAMA Ophthalmology. 2026;144(4):299. https://doi.org/10.1001/jamaophthalmol.2026.0001
  5. 5. Patient and Neighborhood Factors Influencing Glaucoma Medication Adherence. Journal of Glaucoma. 2026;35(8):589-597. https://doi.org/10.1097/ijg.0000000000002731
  6. 6. Patterns of Glaucoma Treatment Use in Asian American Patients With Primary Open-Angle Glaucoma. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2026;10(5):100745. https://doi.org/10.1016/j.mayocpiqo.2026.100745
  7. 7. Sociodemographic differences in glaucoma awareness and knowledge among the general population of Nepal: A population-based study. Journal of Public Health Research. 2026;15(3):22799036261470474. https://doi.org/10.1177/22799036261470474
  8. 8. Comparison of portable devices with standard glaucoma diagnostic testing for the detection of glaucoma for the purposes of glaucoma case finding in low-and middle- income countries. Eye. 2026;40(7):1057-1066. https://doi.org/10.1038/s41433-026-04297-4
  9. 9. Ophthalmology specialty training for general practitioners in China: current status and the Shenzhen model. BMC Primary Care. 2026;27(1):117. https://doi.org/10.1186/s12875-026-03232-6
  10. 10. TeleGlaukos: A Clinician-Led Adaptive Telemonitoring Platform for Hybrid Glaucoma Care. Bioengineering. 2026;13(9):1090. https://doi.org/10.3390/bioengineering13091090
  11. 11. The Impact of the COVID-19 Pandemic on Adherence and Persistence to Glaucoma Therapy: A Retrospective Italian Cohort Study. Advances in Therapy. 2026;43(10):4633-4645. https://doi.org/10.1007/s12325-026-03685-2
  12. 12. Evaluation of the Benefits of a Pharmacist-led Educational Program on Achievement of Intra-ocular Pressure Target among Patients with Open Angle Glaucoma: A Qusai-experimental Study. Journal of Research in Pharmacy Practice. 2026;15(1). https://doi.org/10.4103/jrpp.jrpp_64_25
  13. 13. Establishing Consensus on the Appropriate Tool for Measuring Adherence to Glaucoma Medication in a Sub‐Saharan African Population: A Multidisciplinary Delphi–Based Study. Public Health Challenges. 2026;5(2):e70222. https://doi.org/10.1002/puh2.70222
  14. 14. Association of Comprehensive Geriatric Assessment with Knowledge- and Technique-Related Eye Drop Adherence Problems in Glaucoma Assessed Using the Shimane University Glaucoma Eye Drop Adherence Questionnaire. Journal of Clinical Medicine. 2026;15(13):5203. https://doi.org/10.3390/jcm15135203
  15. 15. Quality of Care in Patients With Newly Diagnosed Glaucoma. JAMA Ophthalmology. 2025;143(11):893. https://doi.org/10.1001/jamaophthalmol.2025.2995

Claim-to-source matrix

What each source supports

Every sourced claim in the new sections maps to the references that support it, the section where it is used, and the limitation a reader should keep in mind. Original executive guidance carries no sources because it is guidance, not a finding.

Claim-to-source matrix
Claim groupSourcesYearsUsed inLimitation
Follow-up, loss to follow-up and pressure reduction by wealth and rurality[15]2025Current evidenceRetrospective multi-system cohort of 1,466 patients; nonmedical variables may be confounded.
Pharmacy-based adherence and subsequent laser and surgical procedures[3]2026Current evidenceSingle academic institute; retrospective association, not causation.
Pandemic disruption of glaucoma therapy persistence and initiation[11]2026Current evidenceAdministrative data from one Italian region; dispensing used as proxy for use.
Patient and neighborhood barriers and facilitators to adherence[5]2026Current evidenceMixed-methods pilot with 44 participants who reported low adherence.
Portable devices for glaucoma case finding[8]2026Continuum of careHospital-based study in Nigeria; community validation pending.
Primary care training and AI-enabled community screening[9]2026Human infrastructureDescriptive program evaluation in one Chinese city; detection rate not specific to glaucoma.
Telemonitoring between visits[10]2026Continuum of carePilot of 30 patients; effectiveness and safety not yet evaluated.
Home virtual reality perimetry adherence and agreement[2]2026Continuum of careSingle prospective cohort of 53 patients; selected participants.
Geographic access to glaucoma specialists[1]2026AccessCounty centroid drive times to society members; excludes other eye care clinicians.
Coaching by a nonphysician counselor and medication adherence[4]2026AccessTwo Michigan health systems; six-month outcome; nonmasked trial.
Pharmacist-led education for drop technique and adherence[12]2026AccessSmall quasi-experimental pilot without a control group; reported percentages not used here.
Treatment use among Asian American patients[6]2026Equity and trustRetrospective records network with diagnosis codes; propensity matching cannot remove all confounding.
Population glaucoma awareness and knowledge[7]2026Equity and trustNepal survey conducted in 2017 and 2018; household heads only.
Cognition, comorbidity and eye-drop adherence problems[14]2026Human infrastructureSingle Japanese hospital; retrospective; new questionnaire.
Measuring glaucoma medication nonadherence[13]2026Public communicationExpert consensus of 16 panelists in a sub-Saharan African context.
Greg Wahlstrom in his office at The Healthcare Executive

About the author

Greg Wahlstrom

MBAHCM

President and Chief Executive Officer, The Healthcare Executive

©2014 – 2026 The Healthcare Executive. All rights reserved.

Back to the contents

Health Observance Calendar

See next month’s observances before it starts.

One email ahead of each month with the health observances coming up and the executive briefs that go with them.

Sent by The Healthcare Executive. Unsubscribe at any time. See our Privacy Policy.